Investors

Corporate Profile

Clene is a clinical-stage biopharmaceutical company dedicated to revolutionizing the treatment of neurodegenerative diseases to restore and protect neuronal health and function. Our nanotherapeutics target cellular energy impairments that are common to many diseases.

News Releases

April 16, 2024
Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting
Long term extension of the Phase 2 VISIONARY-MS clinical trial of CNM-Au8 demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p...
March 15, 2024
Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®
Proprietary catalytic gold nanocrystals comprising Clene’s investigational drug CNM-Au8 ® develop a protein corona upon exposure to human blood plasma comprised of proteins that promote blood-brain barrier penetration, an important feature of the drug’s neuroprotective mechanism of action The...
March 13, 2024
Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights
Initiated discussions with FDA regarding accelerated approval pathway for CNM-Au8 ® for the treatment of ALS with the objective of submitting an NDA in 2024 Released long-term data from the open-label extension of the HEALEY ALS Platform Trial in which CNM-Au8 demonstrated statistically significant...

Investor Presentation

Revolutionizing the treatment of neurodegenerative diseases to restore and protect neuronal health and function.

Download PDF